Old Web
English
Sign In
Acemap
>
authorDetail
>
R.G. Lima
R.G. Lima
Eli Lilly and Company
Ixekizumab
Medicine
Psoriasis Area and Severity Index
Adverse effect
Dermatology
3
Papers
72
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS).
2020
British Journal of Dermatology
Amy S. Paller
Marieke M.B. Seyger
G. A Magariños
Jerry Bagel
Andreas Pinter
Jennifer Clay Cather
S. Keller
C.R. Capriles
R.G. Lima
Gaia Gallo
C.A. Little
Emily Edson-Heredia
L. Li
Wen Xu
K.A. Papp
Show All
Source
Cite
Save
Citations (27)
A Head‐to‐Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate‐to‐Severe Plaque Psoriasis: 24‐Week Efficacy and Safety Results from a Randomised, Double‐Blinded Trial
2020
British Journal of Dermatology
Andrew Blauvelt
C. Leonardi
Boni E. Elewski
Jeffrey J. Crowley
Lyn Guenther
M. Gooderham
Richard G. Langley
Ronald Vender
Andreas Pinter
Cem Griffiths
Yayoi Tada
H. Elmaraghy
R.G. Lima
Gaia Gallo
L. Renda
Russel Burge
S. Y. Park
Baojin Zhu
Kim A. Papp
Show All
Source
Cite
Save
Citations (0)
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
2020
British Journal of Dermatology
Andrew Blauvelt
K.A. Papp
Alice B. Gottlieb
Jarell A
Kristian Reich
Maari C
Kenneth B. Gordon
Laura K. Ferris
Richard G. Langley
Yayoi Tada
R.G. Lima
Elmaraghy H
Gaia Gallo
Lisa Renda
Park Sy
Russel Burge
Jerry Bagel
Show All
Source
Cite
Save
Citations (45)
1